Results 1 to 10 of about 79,477 (216)
Long‐acting growth hormone in 2022 [PDF]
Pediatric Investigation, 2023 After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency.
Margaret Steiner +2 more
doaj +5 more sources
Long acting growth hormone (LAGH), an update [PDF]
Frontiers in Pediatrics, 2023 In 1957, Maurice Raben at Yale was able to isolate and purify growth hormone from cadaveric pituitary glands. Pituitary growth hormone was the only way to treat children with growth hormone (GH) deficiency, until 1985 when recombinant GH became available
Margaret Steiner Grillo +2 more
doaj +6 more sources
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation [PDF]
Frontiers in Endocrinology, 2022 Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life.
Martin Bidlingmaier +6 more
doaj +7 more sources
Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs [PDF]
Frontiers in Endocrinology, 2021 Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects.
Kevin C. J. Yuen +3 more
doaj +5 more sources
Perspectives on long-acting growth hormone therapy in children and adults [PDF]
Archives of Endocrinology and Metabolism, 2020 Growth hormone therapy with daily injections of recombinant human growth hormone has been available since 1985, and is shown to be safe and effective treatment for short stature in children and for adult growth hormone deficiency. In an effort to produce
Rayhan A. Lal, Andrew R. Hoffman
doaj +7 more sources
Treatment with long-acting growth hormone: effectiveness and safety [PDF]
Frontiers in EndocrinologyLong-acting growth hormone (GH) formulations represent a clinically effective alternative to daily recombinant human GH (rhGH) administration, enabling extended dosing intervals and enhancing patient adherence. This approach is particularly beneficial in
Livia Basile +5 more
doaj +3 more sources
Rationale for Long-acting Growth Hormone Therapy and Future Aspects [PDF]
JCRPERecombinant growth hormone (GH) is administered as daily subcutaneous injections. Daily treatment can be challenging for children/adolescents, as well as for parents and/or caregivers, such as legal representatives or guardians of children in ...
Semra Çetinkaya +3 more
doaj +4 more sources
Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone [PDF]
ChildrenBackground: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat,
Atilla Büyükgebiz, And Demir
doaj +4 more sources
Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency [PDF]
Journal of the Endocrine SocietyAbstract Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct; additional moieties or mechanisms that prolong LAGH action confer unique pharmacodynamic ...
Sarah Cadarette
exaly +4 more sources
What do we do now that the long-acting growth hormone is here? [PDF]
Frontiers in Endocrinology, 2022 In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj +2 more sources